What happened to IDEC Pharmaceuticals?

The pharmaceutical company merger spree has produced corporate names like GlaxoSmithKline and AstraZeneca. Now the biotechnology industry is getting its own combination nameplate — Biogen Idec.

What does Biogen company do?

Biogen specializes in therapies for neurological and neurodegenerative diseases. Biogen is a biotechnology company that makes only a handful of advanced drugs to treat patients with neurological diseases. More than half of Biogen’s revenues come from its drugs used to treat multiple sclerosis (MS).

What does Biogen stand for?

: a hypothetical ultimate living unit of which cells are built up : biophore.

How do I contact Biogen?

You can reach a Biogen Support Coordinator Monday through Friday from 8:30 AM until 8 PM ET, or you can reach a Nurse Educator 24/7 at 1-800-456-2255.

Is Biogen Idec the same as Biogen?

CAMBRIDGE, Mass. –(BUSINESS WIRE)–Effective today, Biogen Idec is known simply as Biogen (NASDAQ: BIIB). Biogen Idec was created in 2003 through the merger of Biogen and IDEC Pharmaceuticals, creating one of the world’s leading research-based life sciences organizations. …

Is Biogen owned by Roche?

Acquired in acquisition of Fumapharm AG in 2006. The first medicine approved with the FDA’s Breakthrough Therapy Designation and is also currently in Phase 3 trials for NHL and diffuse large B-cell lymphoma. Currently commercialized in the United States by Genentech, a wholly owned subsidiary of Roche.

Will aducanumab get approved?

Today, the U.S. Food and Drug Administration approved Aduhelm (aducanumab) for the treatment of Alzheimer’s, a debilitating disease affecting 6.2 million Americans.

Is aducanumab available?

While the drug has been approved by the FDA, it is not yet available to patients. The timeline for the drug to be made available by the drug company is not yet clear. It could be several months. Will patients be able to get aducanumab at the Alzheimer’s Disease Research Center (ADRC)?

Will Biogen get FDA approval?

Biogen’s stock surged last month after the FDA approved the biotech company’s drug, the first medication cleared by U.S. regulators to slow cognitive decline in people living with Alzheimer’s and the first new medicine for the disease in nearly two decades.

Where is Biogen located in the US?

Cambridge, Massachusetts
Biogen Idec Inc. Cambridge, Massachusetts, U.S. Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.

Who is the CEO of Biogen?

Michel Vounatsos (Jan 6, 2017–)
Biogen/CEO

Biogen CEO Michel Vounatsos joins CNBC’s Meg Tirrell on ‘Power Lunch’ to discuss the FDA’s decision to approve the company’s Alzheimer’s drug.

When did Biogen merge with Idec?

2003
Biogen Idec was created in 2003 through the merger of Biogen and IDEC Pharmaceuticals, creating one of the world’s leading research-based life sciences organizations. The company has since focused its research and commercial efforts in three core areas: neurology, immunology and hematology.

What is the mission of Biogen Idec?

At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. We believe that no other disease area holds as much need or as much promise for medical breakthroughs as…

How to contact Biogen for product support?

This product support information is applicable to patients who have been prescribed Biogen therapies in the United States only. For product support in countries outside of the U.S., please contact the Biogen affiliate in your country or email [email protected] if your country is not represented.

Is there a third party site for Biogen?

Third Party Sites. Biogen assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site’s endorsement of Biogen or this website.

When is Biogen going to get approval for aducanumab?

On October 22, 2019, Biogen announced that, after consulting with the U.S. Food and Drug Administration (FDA), Biogen plans to pursue regulatory approval for aducanumab, an investigational treatment for early Alzheimer’s disease. Read the full press release.